期刊文献+

肝癌患者粘附性LAK细胞制备及抗瘤活性研究 被引量:1

Preparation and Anti-tumor Activity of Adherent LAK Cells from Patients with Hepatocellular Carcinoma
在线阅读 下载PDF
导出
摘要 本研究在常规LAK细胞制备基础上进行改进,用苯丙氨酸甲酯(PME)去除肝癌患者外周血中抑制LAK细胞活性的单核巨噬细胞,制备抗癌活性较高扩增迅速的粘附性LAK细胞,从实验结果分析,外周血处理后粘附性LAK细胞较未粘性LAK细胞具有较强的扩增能力,最大扩增倍数23~243倍,同时粘附性LAK细胞中T_H细胞亚群有增加趋势,T_S细胞亚群有减少趋势,其IL-2R^+表达增加至64.3%,此外,在抗瘤活性方面粘附性LAK细胞与非粘附性LAK细胞存在一定差别,分别为64.6%和42.8%,因此,从临床实用出发,制备相对高效的粘附性LAK细胞可以提高LAK疗法的治疗效果。 Highly active adherent LAK cells (A-LAK) with monocytes depleted by phenylalahine methyl ester (PME) were cultured from peripheral blood lymphocytes of patients with hepatocellular carcinoma (HCC). Results showed that A-LAK cells cultured in about 14 days had expanded better and faster than that of nonadherent LAK cells (NA-LAK) with their greatest expansion varied from 23 to 243 fold .A-LAK cells showed a trend of increase in TH cell subgroup and decrease in Ts cell sub-group as well as significant difference of TH/TS ratio. The IL-2R expression increased from 34.1%to 64.3%. A-LAK cells had a higher cytotoxicity (64.6%)than that of NA-LAK cells (42.8%).Further clinical application of A-LAK cells may improve biotherapeutic effect on HCC patients compared with that of NA-LAK cells .
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 1995年第3期191-193,共3页 Chinese Journal of Cancer Biotherapy
基金 美国中华医学基金会资助课题(93-583)
关键词 LAK细胞 肝癌患者 抗瘤活性 扩增 外周血 粘附性 细胞亚群 制备 甲酯 研究 adherent LAK cells (A-LAK) phenylalanine methyl ester (PME) hepatocellular carcinoma (HCC)
  • 相关文献

同被引文献3

  • 1王一,陈汉,吴孟超,宝建中,丛文铭,王皓,张秀忠.肝癌肿瘤浸润淋巴细胞的研究与应用[J].中华外科杂志,1995,33(1):29-31. 被引量:16
  • 2T. Sch?ndorf,Heike Engel,Carsten Lindemann,Hannelore Kolhagen,Alexander A. von Rücker,Peter Mallmann. Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours[J] 1997,Cancer Immunology, Immunotherapy(2):88~96
  • 3Emmanuel Katsanis,Maria A. Bausero,Hong Xu,Paul J. Orchard,Zhiyi Xu,R. Scott Melvor,Adrienne A. Brian,Bruce R. Blazar. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing[J] 1994,Cancer Immunology Immunotherapy(2):135~141

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部